Precision BioSciences Doses First Patient in Phase 1/2 FUNCTION-DMD Clinical Trial
Precision BioSciences, Inc. (Nasdaq: DTIL) announced that the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD) at Arkansas Children's Hospital.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.